Abstract
Palivizumab is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus infection in infants. The potential for palivizumab to interfere with commercially available respiratory syncytial virus diagnostic tests was demonstrated. Negative test results in palivizumab-treated subjects should be interpreted with caution and confirmed by a nucleic acid amplification-based assay.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / chemistry*
-
Antibodies, Viral / blood
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / chemistry
-
Humans
-
Immunoassay / methods*
-
Nasal Cavity / immunology
-
Nasal Cavity / virology
-
Palivizumab
-
Reagent Kits, Diagnostic
-
Respiratory Syncytial Virus Infections / diagnosis*
-
Respiratory Syncytial Virus Infections / drug therapy
-
Respiratory Syncytial Virus Infections / immunology
-
Respiratory Syncytial Virus Infections / virology
-
Respiratory Syncytial Viruses / immunology
-
Respiratory Syncytial Viruses / isolation & purification*
-
Sensitivity and Specificity
-
Virology / methods*
Substances
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Viral
-
Antiviral Agents
-
Reagent Kits, Diagnostic
-
Palivizumab